Thetis Awarded Key Composition of Matter Patents on Resolvin-based Agents

Provides a platform for the development of Resolvin therapies in inflammatory bowel disease and other inflammation disorders BRANFORD, CT – (January 22, 2019) – Thetis Pharmaceuticals, a privately-held biopharmaceutical company developing novel small molecule therapies based on a class of potent pro-resolving lipid mediators known as Resolvins, announced today that the U.S. Patent and Trademark […]

Thetis Selected to Present TP-317 Program at IBD Innovate Conference

Novel Resolvin-based drug candidate offers potential first-in-class, oral, small molecule therapy for IBD BRANFORD, CT – (November 13, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing novel Resolvin-based therapies to treat inflammatory diseases, was selected by the Crohn’s & Colitis Foundation to present on TP-317, its lead drug candidate for inflammatory bowel disease […]

Thetis Awarded Key Patent on HEALER Technology

BRANFORD, CT – (July 17, 2018) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal diseases, announced today that the USPTO has granted patent US  9,999,626 providing composition of matter protection for its IBD development candidates. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids with 16 […]

Thetis Receives $1.9 Million Fast-Track NIH Grant to Advance Novel IBD Drug Pipeline Toward Clinical Investigation

First-in-human studies targeted for 2019 BRANFORD, CT – (GlobeNewswire – May 23, 2018) – Thetis Pharmaceuticals, a biopharmaceutical company developing novel therapies for treatment of inflammatory bowel disease (IBD), today announced the receipt of a Fast-Track Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH). The award provides up to $1.9 […]

FDA & Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director

Former FDA GI Division Director and V.P. of U.S. Regulatory Strategy at Pfizer to Guide Clinical and Regulatory Development of Thetis IBD Programs BRANFORD, CT – (GlobeNewswire – May 7, 2018) – Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing first-in-class, immuno-resolving small molecule drugs to treat inflammatory bowel disease (IBD), announced today that Brian […]